



Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

April 2, 2025

BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.

Poster Presentation Details

Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates

Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT

Session: Targeted Therapies and Combinations 2

Location: Poster Section 34

Abstract 4361 – Development and application of a mechanistic pharmacokinetic pharmacodynamic (PKPD) model to predict anti-chronic myeloid leukemia (CML) effects of tyrosine kinase inhibitors

Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT

Session: Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics

Location: Poster Section 20

Abstract LB295 – ELV-3111, a type 1 pan-RAF inhibitor, that safely combines with MEK inhibitors for enhanced anti-tumor activity in NRAS and BRAF mutant cancers including the most common mechanisms of BRAF inhibitor clinical resistance

Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT

Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3

Location: Poster Section 52

Abstract LB294 – Mechanism of tumor-selective inhibition of dimeric RAF by a Type 1 RAF inhibitor

Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT

Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3

Location: Poster Section 52

Abstract 5515 – ELVN-001, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia alone or in combination with asciminib

Date/Time: Tuesday, April 29, 2025, 2:00 p.m. – 5:00 p.m. CDT

Session: Drug Resistance in Molecular Targeted Therapies 3

Location: Poster Section 17

Abstracts are currently available on the AACR [website](#). Following the presentations, copies will be available on the "[Program Presentations & Publications](#)" section of the Company's website at www.enliventherapeutics.com.

About Enliven Therapeutics

Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-poster-presentations-at-the-2025-aacr-annual-meeting-302419011.html>

SOURCE Enliven Therapeutics, Inc.

Investors, ir@enliventherapeutics.com; Media, media@enliventherapeutics.com